Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study

Published:2021-11 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Talpaz Moshe^ORCID,Prchal Josef^ORCID,Afrin Lawrence,Arcasoy Murat,Hamburg Solomon^ORCID,Clark Jason,Kornacki Deanna,Colucci Philomena,Verstovsek Srdan

Funder

Bristol-Myers Squibb

Novartis

Intel Corporation

Incyte Corp

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. Myelofibrosis: clinicopathologic features, prognosis, and management;O'Sullivan;Clin Adv Hematol Oncol,2018

2. Prognosis of primary myelofibrosis in the genomic era;Bose;Clin Lymphoma Myeloma Leuk,2016

3. Management of myelofibrosis: JAK inhibition and beyond;Stahl;Expert Rev Hematol,2017

4. Recent advances in the diagnosis and management of primary myelofibrosis;Takenaka;Korean J Intern Med,2018

5. Guideline for the diagnosis and management of myelofibrosis;Reilly;Br J Haematol,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-04-12

2. Recurrent Postoperative Hemorrhage After Mohs Reconstruction in a Patient on Ruxolitinib;OTO Open;2024-04

3. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety;Journal of Hematology & Oncology;2023-07-27

4. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy;Leukemia & Lymphoma;2023-04-20

5. New approaches to tackle cytopenic myelofibrosis;Hematology;2022-12-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3